CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma (Q41411254)

30 September 2017

CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma (English)

1 reference

30 September 2017

Xuan J Wang

1

1 reference

30 September 2017

Adam C Seegmiller

series ordinal

2

1 reference

30 September 2017

Nishitha M Reddy

series ordinal

3

1 reference

30 September 2017

Shaoying Li

series ordinal

4

1 reference

30 September 2017

5 September 2015

1 reference

European Journal of Haematology

30 September 2017

1 reference

30 September 2017

97

1 reference

30 September 2017

1

1 reference

30 September 2017

39-47

1 reference

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

30 September 2017

1 reference

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

21 January 2018

1 reference

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.

21 January 2018

1 reference

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

21 January 2018

1 reference

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

Double-hit B-cell lymphomas

21 January 2018

1 reference

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

21 January 2018

1 reference

MYC/BCL2 double-hit high-grade B-cell lymphoma

21 January 2018

1 reference

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

21 January 2018

1 reference

CD30+ lymphoproliferative disorders

21 January 2018

1 reference

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

21 January 2018

1 reference

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases

21 January 2018

1 reference

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

21 January 2018

1 reference

CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia

21 January 2018

1 reference

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

21 January 2018

1 reference

B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.

21 January 2018

1 reference

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Con

21 January 2018

1 reference

Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies

21 January 2018

1 reference

MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.

21 January 2018

1 reference

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

21 January 2018

1 reference

Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/EJH.12680

1 reference

30 September 2017

1 reference